Emergent BioSolutions (EBS) Tops Q4 EPS by 19c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.52 +6.37%
EPS Growth %: -31.3%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -31.3%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.67, $0.19 better than the analyst estimate of $0.48. Revenue for the quarter came in at $151.7 million versus the consensus estimate of $120.45 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
